Screener
UroGen Pharma URGN CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash Flows From Investing Activities | ||
| Purchases of marketable securities | (24,780) | (68,140) |
| Maturities of marketable securities | 5,879 | 70,768 |
| Purchases of property and equipment | (114) | (185) |
| Net cash (used in) provided by investing activities | (19,015) | 2,443 |
| Cash Flows From Financing Activities | ||
| Principal payments on finance leases | (708) | — |
| Proceeds from exercise of options into ordinary shares | 1,066 | 327 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's capex?
- UroGen Pharma (URGN) reported capex of $60K in Q2 2026.
- How has UroGen Pharma's capex changed year-over-year?
- UroGen Pharma's capex decreased by 57.4% year-over-year, from $141K to $60K.
- What is the long-term trend for UroGen Pharma's capex?
- Over 4 years (2021 to 2025), UroGen Pharma's capex has grown at a -21.3% compound annual growth rate (CAGR), from $752K to $289K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about UroGen Pharma's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude